Filed in archive
Studies
, Treatment
by Gloria Gamat on July 19, 2006
Cardevaâ„¢ (a human serum albumin (HSA)-BNP fusion protein) the most advanced compound in CoGenesys' broad pipeline of improved, long-acting biopharmaceuticals being developed to address unmet medical needs across a broad spectrum of therapeutic areas, have demonstrated in preclinical studies the ability to retain the pharmacological profile of BNP peptide while maintaining a greatly extended half-life and long duration of action.
"BNP stimulates cyclic GMP, which is not only a vasodilator but an inhibitor of the progressive heart muscle structural remodeling that leads to progression of heart failure," according to Jay N. Cohn, M.D., Professor of Medicine at the University of Minnesota.
"Chronic administration of a long- acting BNP could have remarkably favorable effects that must be documented in clinical trials," he said.
Cardevaâ„¢ holds great promise in the treatment of chronic heart failure (CHF) and CoGenesys, Inc. can't wait to get on with the clinical trials and have this available to CHF patients in due time.
Read more at CoGenesys, Inc. (a pdf file)
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/29755
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Cardevaâ„¢ for Chronic Heart Failure (CHF), Clinical Trial On-going:
|
Rating: 6.33 out of 3 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
